- Details
- Stephen Williams sits down with Alicia Morgans to share some of the bladder cancer highlights from AUA 2022. Dr. Williams touches on a variety of topics in both muscle-invasive bladder cancer and non-muscle-invasive bladder cancer, including data from the QUILT study at UCLA, a pilot study on a comprehensive geriatric assessment tool at the University of Washington, the importance of psychological...
|
- Details
- In this discussion with Ashish Kamat, Tullika Garg presents on bladder cancer in the older adult population. Garg and Kamat discuss special considerations when diagnosing and treating this patient population and the differences in older cancer patients from their younger counterparts, due to geriatric conditions. Garg highlights that patients following cancer treatment, report, they have poorer ph...
|
- Details
- Barton Grossman joins Ashish Kamat in highlighting the 25th anniversary of the International Bladder Cancer Network (IBCN). The 2022 meeting is being held again in Barcelona, Spain, from September 29 – October 1. Dr. Grossman shares reflections on the cooperative efforts of the Bladder Cancer Marker Network of the National Cancer Institute (NCI), which focuses on developing and assessing biomarker...
|
- Details
- Kamal Pohar moderates a conversation with Brant Inman and Yair Lotan. The experts delve into the role of radical cystectomy for clinical N1 or N2 bladder cancer. Dr. Inman advocates for cystectomy combined with lymph adenectomy after systemic therapy, emphasizing its potential for better patient outcomes. Dr. Lotan, however, raises concerns about the heterogeneity in node positivity and the limita...
|
- Details
- Lauren Cooley joins Alicia Morgans for a discussion on gender differences in bladder cancer. Men are far more likely to be diagnosed with bladder cancer compared to women. Yet when women are diagnosed with bladder cancer, they are usually older and their disease is more advanced. Dr. Cooley explains how her research uses a mouse model to explore potential genetic and immunologic differences in the...
|
- Details
- Sam Chang joins Ashish Kamat to discuss the results of the QUILT study, which he presented at the GU ASCO 2022 annual meeting. QUILT 3.032 is an open-label, multicenter phase 3 study of intravesical bacillus calmette-guerin (BCG) plus N-803 in patients with BCG-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC) (NCT03022825) with CIS and papillary disease. Given the observed strong...
|
- Details
- Anirban P Mitra joins Ashish Kamat in highlighting the University of Southern California's experience in the management trends and outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. This has been updated to reflect current practice patterns, including neoadjuvant, adjuvant therapy, and stage migration. This study looked at clinical-pathological as well as o...
|
- Details
- Sam Chang and Jeffrey Holzbeierlein discuss the comparative effectiveness of neoadjuvant chemotherapy for bladder cancer, as well as for upper urinary tract urothelial carcinoma. Dr. Holzbeierlein goes into depth on the background of neoadjuvant treatment for these diseases, as well as a look at the POUT trial. They also discuss future projects and exciting new studies. Biographies: Jeffrey Holzbe...
|
- Details
- In this discussion with Sam Chang on the prevention of bladder recurrence, Aditya Bagrodia starts off with a case study of a 69-year-old female in generally good health, presents with hematuria, well-controlled diabetes, hypertension, remote history of smoking, and importantly, no history of upper tract urothelial cancer in the family or other Lynch syndrome-associated malignancies. Drs. Bagrodia...
|
- Details
- Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extremely low rates of progression and cancer-specific mortality; however, patients with low-risk NMIBC may often receive non-guideline-recommended and potentially costly surveillance testing and treatment. The objective of this study was to describe current surveillance and treatment practices, cancer outcomes, and costs of ca...
|
